These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 25852859)
21. [Drug-induced renal calculi]. Servais A; Daudon M; Knebelman B Ann Urol (Paris); 2006 Apr; 40(2):57-68. PubMed ID: 16709005 [TBL] [Abstract][Full Text] [Related]
22. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice. Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070 [TBL] [Abstract][Full Text] [Related]
23. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. Youle M J Antimicrob Chemother; 2007 Dec; 60(6):1195-205. PubMed ID: 17890281 [TBL] [Abstract][Full Text] [Related]
24. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study. Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D; HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965 [TBL] [Abstract][Full Text] [Related]
25. [Renal colic and lithiasis in HIV(+)-patients treated with protease inhibitors]. González Enguita C; Jiménez Jiménez I; Pérez Pérez J; Montero Rubio R; Cancho Gil MJ; Vela Navarrete R Actas Urol Esp; 2000 Mar; 24(3):212-8. PubMed ID: 10870227 [TBL] [Abstract][Full Text] [Related]
26. Indinavir urolithiasis: an emerging cause of renal colic in patients with human immunodeficiency virus. Kohan AD; Armenakas NA; Fracchia JA J Urol; 1999 Jun; 161(6):1765-8. PubMed ID: 10332431 [TBL] [Abstract][Full Text] [Related]
27. Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment. Daudon M; Frochot V; Bazin D; Jungers P Drugs; 2018 Feb; 78(2):163-201. PubMed ID: 29264783 [TBL] [Abstract][Full Text] [Related]
28. [Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain]. Smets E; Brogan AJ; Hill A; Adriaenssen I; Sawyer AW; Domingo-Pedrol P; Gostkorzewicz J; Ledesma F Enferm Infecc Microbiol Clin; 2013; 31(7):430-6. PubMed ID: 23260386 [TBL] [Abstract][Full Text] [Related]
30. HIV protease inhibitors: recent clinical trials and recommendations on use. Fernández-Montero JV; Barreiro P; Soriano V Expert Opin Pharmacother; 2009 Jul; 10(10):1615-29. PubMed ID: 19527188 [TBL] [Abstract][Full Text] [Related]
31. Do stones still kill? An analysis of death from stone disease 1999-2013 in England and Wales. Kum F; Mahmalji W; Hale J; Thomas K; Bultitude M; Glass J BJU Int; 2016 Jul; 118(1):140-4. PubMed ID: 26765522 [TBL] [Abstract][Full Text] [Related]
32. [Renal staghorn calculi in small children - presentation of two cases]. Krzemień G; Szmigielska A; Jankowska-Dziadak K; Pańczyk-Tomaszewska M Dev Period Med; 2016; 20(1):23-6. PubMed ID: 27416622 [TBL] [Abstract][Full Text] [Related]
33. Quality control of protease inhibitors. Yekkala R; Adams E; Van Schepdael A; Hoogmartens J J Pharm Sci; 2008 Jun; 97(6):2012-21. PubMed ID: 17828738 [TBL] [Abstract][Full Text] [Related]
34. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. Turner D; Schapiro JM; Brenner BG; Wainberg MA Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893 [TBL] [Abstract][Full Text] [Related]
35. Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS. Jayakanthan M; Chandrasekar S; Muthukumaran J; Mathur PP J Mol Graph Model; 2010 Jan; 28(5):455-63. PubMed ID: 19931478 [TBL] [Abstract][Full Text] [Related]
36. EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. Türk C; Petřík A; Sarica K; Seitz C; Skolarikos A; Straub M; Knoll T Eur Urol; 2016 Mar; 69(3):468-74. PubMed ID: 26318710 [TBL] [Abstract][Full Text] [Related]
37. Diagnosis and management of non-calcium-containing stones in the pediatric population. Ranabothu S; Bernstein AP; Drzewiecki BA Int Urol Nephrol; 2018 Jul; 50(7):1191-1198. PubMed ID: 29846891 [TBL] [Abstract][Full Text] [Related]
38. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW; JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381 [TBL] [Abstract][Full Text] [Related]
39. Urolithiasis in HIV-positive patients treated with atazanavir. Couzigou C; Daudon M; Meynard JL; Borsa-Lebas F; Higueret D; Escaut L; Zucman D; Liotier JY; Quencez JL; Asselah K; May T; Neau D; Vittecoq D Clin Infect Dis; 2007 Oct; 45(8):e105-8. PubMed ID: 17879904 [TBL] [Abstract][Full Text] [Related]